Special issues in fertility preservation for gynecologic malignancies

Federica Tomao, Fedro Peccatori, Lino del Pup, Dorella Franchi, Vanna Zanagnolo, Pierluigi Benedetti Panici, Nicoletta Colombo

Research output: Contribution to journalArticle

Abstract

Gynecologic malignancies account for 1,09 million new cancer cases worldwide consisting of about 12% of tumors affecting female population. About 10% of all female cancer survivors are younger than 40 years of age. Since cancers affecting female genital organs are usually treated by radical surgery, chemotherapy or chemoradiation approaches that induce permanent damage of reproductive functions, the development of strategies for fertility preservation represent one of the most important goals for gynecologic oncology. In this scenario, the newly defined oncofertility discipline acquires increasing interest, offering patients maximal chances to make an adequate decision about future fertility, based on their oncologic diagnosis and prognosis. However, the majority of physicians do not pay particular attention to these issues, even if impressive progresses have been made in this field in the last decades. Possibly, it is due to the lack of strong evidences from clinical trials without an adequate number of cases to establish safety and efficacy of these procedures. In this review we will discuss the most recently debated options for fertility preservation in gynecologic oncology, highlighting issues and controversies related to oncofertility.

Original languageEnglish
Pages (from-to)206-219
Number of pages14
JournalCritical Reviews in Oncology/Hematology
Volume97
DOIs
Publication statusPublished - Jan 1 2016

Keywords

  • Borderline ovarian tumor
  • Cervical cancer
  • Endometrial cancer
  • Fertility sparing
  • Malignant ovarian germ cell tumors
  • Ovarian cancer
  • Uterus transplantation

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Special issues in fertility preservation for gynecologic malignancies'. Together they form a unique fingerprint.

Cite this